📊 CLPT Key Takeaways
Is ClearPoint Neuro, Inc. (CLPT) a Good Investment?
ClearPoint Neuro is a pre-revenue profitability company with severe operational challenges despite solid gross margins of 61.4%. The company is burning significant cash with negative operating cash flow of -$23.9M and free cash flow of -$24.4M, while flat revenue growth and deteriorating net income (-35% YoY) indicate deteriorating fundamentals. With only 45.9M in cash against 49.1M in long-term debt and persistent operating losses of -$24.2M, the company faces severe liquidity stress if losses continue at current rates.
ClearPoint Neuro shows decent product-level economics with a 61.4% gross margin, but those economics are being overwhelmed by operating costs, producing deeply negative operating and net margins on flat revenue. Financial health is mixed: liquidity is strong with $45.92M of cash and a 5.91x current ratio, but leverage is meaningful at 1.75x debt/equity and cash burn remains heavy. Until revenue growth reaccelerates and losses narrow materially, the fundamentals look weak rather than durable.
Why Buy ClearPoint Neuro, Inc. Stock? CLPT Key Strengths
- Strong gross margin of 61.4% indicates efficient production and pricing power
- Solid cash position of $45.9M provides near-term runway
- Excellent liquidity ratios (current ratio 5.91x, quick ratio 5.13x) for short-term obligations
- Strong liquidity position with $45.92M in cash and high current and quick ratios
- Healthy gross margin suggests the core products have solid underlying unit economics
- Asset base remains supported by positive equity despite ongoing losses
CLPT Stock Risks: ClearPoint Neuro, Inc. Investment Risks
- Negative operating income of -$24.2M with no clear path to profitability despite adequate gross margins
- Severe cash burn with negative operating cash flow of -$23.9M and free cash flow of -$24.4M
- Stagnant revenue growth (0% YoY) combined with expanding net losses (-35% YoY) indicates operational deterioration
- High leverage with debt-to-equity of 1.75x and long-term debt of $49.1M against stockholders equity of only $28.0M
- Negative interest coverage of -298.3x indicates inability to service debt from operations
- High insider Form 4 activity (29 filings in 90 days) may indicate uncertainty or distress
- Flat revenue combined with very large operating losses indicates poor operating leverage
- Negative operating cash flow and free cash flow suggest continued dependence on external capital or balance-sheet resources
- High debt relative to equity and negative interest coverage increase financial risk if losses persist
Key Metrics to Watch
- Quarterly revenue growth and customer acquisition trends
- Operating cash flow and path to cash flow breakeven
- Operating margin improvement and SG&A cost reduction progress
- Cash runway given current burn rate and debt maturity schedule
- Gross margin sustainability under competitive pressure
- Revenue growth relative to operating expense growth
- Operating cash burn and free cash flow trend
ClearPoint Neuro, Inc. (CLPT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.91x current ratio provides a solid financial cushion.
CLPT Profit Margin, ROE & Profitability Analysis
CLPT vs Healthcare Sector: How ClearPoint Neuro, Inc. Compares
How ClearPoint Neuro, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ClearPoint Neuro, Inc. Stock Overvalued? CLPT Valuation Analysis 2026
Based on fundamental analysis, ClearPoint Neuro, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ClearPoint Neuro, Inc. Balance Sheet: CLPT Debt, Cash & Liquidity
CLPT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: ClearPoint Neuro, Inc.'s revenue has grown significantly by 54% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.70 indicates the company is currently unprofitable.
CLPT Revenue Growth, EPS Growth & YoY Performance
CLPT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $8.1M | -$4.1M | $-0.18 |
| Q2 2025 | $7.9M | -$4.1M | $-0.16 |
| Q1 2025 | $7.6M | -$4.1M | $-0.16 |
| Q3 2024 | $5.8M | -$4.1M | $-0.18 |
| Q2 2024 | $6.0M | -$4.1M | $-0.16 |
| Q1 2024 | $5.4M | -$4.1M | $-0.16 |
| Q3 2023 | $5.1M | -$3.8M | $-0.15 |
| Q2 2023 | $5.2M | -$4.0M | $-0.18 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ClearPoint Neuro, Inc. Dividends, Buybacks & Capital Allocation
CLPT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for ClearPoint Neuro, Inc. (CIK: 0001285550)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CLPT
What is the AI rating for CLPT?
ClearPoint Neuro, Inc. (CLPT) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 87% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CLPT's key strengths?
Claude: Strong gross margin of 61.4% indicates efficient production and pricing power. Solid cash position of $45.9M provides near-term runway. ChatGPT: Strong liquidity position with $45.92M in cash and high current and quick ratios. Healthy gross margin suggests the core products have solid underlying unit economics.
What are the risks of investing in CLPT?
Claude: Negative operating income of -$24.2M with no clear path to profitability despite adequate gross margins. Severe cash burn with negative operating cash flow of -$23.9M and free cash flow of -$24.4M. ChatGPT: Flat revenue combined with very large operating losses indicates poor operating leverage. Negative operating cash flow and free cash flow suggest continued dependence on external capital or balance-sheet resources.
What is CLPT's revenue and growth?
ClearPoint Neuro, Inc. reported revenue of $37.0M.
Does CLPT pay dividends?
ClearPoint Neuro, Inc. does not currently pay dividends.
Where can I find CLPT SEC filings?
Official SEC filings for ClearPoint Neuro, Inc. (CIK: 0001285550) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CLPT's EPS?
ClearPoint Neuro, Inc. has a diluted EPS of $-0.90.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CLPT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, ClearPoint Neuro, Inc. has a SELL rating with 87% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CLPT stock overvalued or undervalued?
Valuation metrics for CLPT: ROE of -91.1% (sector avg: 15%), net margin of -69.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CLPT stock in 2026?
Our dual AI analysis gives ClearPoint Neuro, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CLPT's free cash flow?
ClearPoint Neuro, Inc.'s operating cash flow is $-23.9M, with capital expenditures of $522.0K. FCF margin is -66.1%.
How does CLPT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -69.1% (avg: 12%), ROE -91.1% (avg: 15%), current ratio 5.91 (avg: 2).
Is ClearPoint Neuro, Inc. carrying too much debt?
CLPT has a debt-to-equity ratio of 1.75x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 5.91 suggests adequate short-term liquidity.